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The relationship of TP53 R72P polymorphism to disease
outcome and TP53 mutation in myelodysplastic syndromes
KL McGraw1, LM Zhang2, DE Rollison3, AA Basiorka1,4, W Fulp5, B Rawal6, A Jerez7, DL Billingsley8, H-Y Lin5, SE Kurtin9, S Yoder2,
Y Zhang5, K Guinta7, M Mallo10, F Solé10, MJ Calasanz11, J Cervera11, E Such11, T González12, TJ Nevill13, T Haferlach14, AE Smith15,
A Kulasekararaj15, G Mufti15, A Karsan13, JP Maciejewski7, L Sokol1, PK Epling-Burnette16, S Wei16 and AF List1
Nonsynonymous TP53 exon 4 single-nucleotide polymorphism (SNP), R72P, is linked to cancer and mutagen susceptibility. R72P
associations with specific cancer risk, particularly hematological malignancies, have been conflicting. Myelodysplastic syndrome
(MDS) with chromosome 5q deletion is characterized by erythroid hypoplasia arising from lineage-specific p53 accumulation
resulting from ribosomal insufficiency. We hypothesized that apoptotically diminished R72P C-allele may influence predisposition to
del(5q) MDS. Bone marrow and blood DNA was sequenced from 705 MDS cases (333 del(5q), 372 non-del(5q)) and 157 controls.
Genotype distribution did not significantly differ between del(5q) cases (12.6% CC, 38.1% CG, 49.2% GG), non-del(5q) cases (9.7%
CC, 44.6% CG, 45.7% GG) and controls (7.6% CC, 37.6% CG, 54.8% GG) (P= 0.13). Allele frequency did not differ between non-del(5q)
and del(5q) cases (P= 0.91) but trended towards increased C-allele frequency comparing non-del(5q) (P= 0.08) and del(5q) (P= 0.10)
cases with controls. Median lenalidomide response duration increased proportionate to C-allele dosage in del(5q) patients (2.2 (CC),
1.3 (CG) and 0.89 years (GG)). Furthermore, C-allele homozygosity in del(5q) was associated with prolonged overall and progression-
free survival and non-terminal interstitial deletions that excluded 5q34, whereas G-allele homozygozity was associated with inferior
outcome and terminal deletions involving 5q34 (P= 0.05). These findings comprise the largest MDS R72P SNP analysis.
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INTRODUCTION
Risk for development of myelodysplastic syndromes (MDS) is
senescence dependent and modified by lifetime exposure to
potential leukemogens or other modifiers. The most common
chromosome abnormality in de novo or therapy-related MDS is an
interstitial deletion involving the long arm of chromosome 5 (del
(5q)). Patients with isolated del(5q) MDS present with clinically and
pathologically distinct features that include severe hypoplastic
anemia, megakaryocyte dysplasia, low risk for leukemia transfor-
mation and a high rate of response to lenalidomide.1,2 Although
haploinsufficiency of several genes in the commonly deleted
region contribute to the disease phenotype, allelic deletion of the
ribosomal processing gene RPS14, a component of the 40S
ribosomal subunit, is a key determinant of ineffective erythropoi-
esis. Nucleolar stress arising from disruption of ribosome assembly
triggers p53 activation, a key effector of erythroid hypoplasia in
both del(5q) MDS and congenital ribosomopathies. A murine
model of the human 5q− syndrome generated by allelic deletion
of the syntenic genes within the commonly deleted region
showed that p53 inactivation is alone sufficient to rescue the
hematologic phenotype, indicating that the hypoplastic anemia of
the 5q− syndrome is p53-dependent.3–8 Furthermore, we recently
reported that acquired resistance to lenalidomide is associated
with restoration of p53 expression.9,10
P53 is a key regulator of stem cell homeostasis that impacts an
array of cellular functions including genomic surveillance, cell-
cycle regulation and apoptotic and inflammatory response. TP53
mutations are well described in human malignancies with up to
50% of all cancers harboring a mutation in the DNA-binding
domain or in one of its regulators affecting p53 function.11,12 In
MDS, TP53 gene mutations are found almost exclusively in
patients with chromosome 5q deletion or a complex karyotype,
and have been associated with lower probability of response to
lenalidomide.13–15 Genome-wide association studies have shown
linkage between single-nucleotide polymorphisms (SNPs) that
alter p53 function and select malignancies. One of the most well-
studied nonsynonymous SNPs, rs1042522 (R72P), located within
codon 72 has been implicated in susceptibility and predisposition
to solid tumors. The R72P TP53 SNP in exon 4 lies proximal to the
DNA-binding domain and adjacent to the proline-rich, proapop-
totic domain of the protein.12,16,17 Substitution of a cytosine
(C allele) for the more common guanine (G allele) results in
translation of a proline (P) rather than arginine (R) residue at
position 72. The amino-acid variants affect the tertiary structure of
the putative p53 Src homology 3-binding domain resulting in
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discernible functional differences. The R/R homozygous genotype
has greater apoptosis-promoting potential than the P/P genotype,
arising in part from intrinsically greater mitochondrial localization
triggering cytosolic release of cytochrome c.16,18 The homozygous
P/P genotype displays greater transcriptional efficiency, inducing a
higher level of G1 arrest than the R/R genotype in a tissue- and
context-specific manner.16,19–23
Previous studies of the R72P variants in hematologic malig-
nancies have shown conflicting results. Patients with chronic
lymphocytic leukemia harboring a homozygous C allele displayed
inferior clinical outcome irrespective of immunoglobulin heavy-
chain variable (IGHV) gene mutation status,24 whereas no similar
relationship was observed in patients with acute myeloid leukemia
(AML).25 In chronic myelogenous leukemia, however, C-allele
homozygozity was associated with decreased overall survival (OS)
and progression-free survival (PFS).26 A meta-analysis of TP53 R72P
association with hematologic malignancy risk validated an
association of R72P with lymphoma risk, but not leukemia.
Previous reports of R72P in MDS involved only small patient
cohorts and did not examine the relationship to chromosome 5q
deletion.27 Given the pathogenetic importance of p53 in del(5q)
MDS, we investigated the distribution of this SNP in patients with
MDS vs controls, and explored the relationship to TP53 mutations,
chromosome 5q deletion, disease features and outcome.
MATERIALS AND METHODS
Study population, tissue specimens and DNA isolation
Peripheral blood and/or bone marrow were collected from patients
(n=705, 372 non-del(5q) and 333 del(5q)) and healthy controls (n=157)
who provided written consent according to Institutional Review Board
(IRB)-approved protocols. Controls were not biologically related to cases
and were either Florida blood bank donors or recruited on Moffitt Cancer
Center clinical trials with IRB consent. All controls were healthy individuals.
MDS cases were collected from hospitals in the United States (Moffitt
Cancer Center (DER and AFL), Cleveland Clinic (JPM) and Arizona Cancer
Center (AFL)), Canada (British Columbia Cancer Center (AK)), Spain
(Hospital de Mar, ICO-Hospital Germans Trias I Pujol, Hospital Universitario
La Fe and Hospital Clinico Universitario Santiago de Compostela (FS)),
Germany (MLL Munich Leukemia Laboratory (TH)) and London (King’s
College Hospital (GM)). DNA was isolated using Qiagen (Valencia, CA, USA)
DNA isolation kits according to the manufacturer’s instructions. Median
follow-up for all patients was 34.7 months for OS and 43.2 months for PFS.
PCR and TP53 genotyping
DNA was amplified using GoTaq Green (Promega Cooperation, Madison,
WI, USA) according to the manufacturer’s protocol. Up to 100ng of DNA
was used to amplify TP53 exon 4 using primers F-5′-CCTGGTCCTCTGACTGC
TCTTTTCACCCA-3′ and R-5′-GGCCAGGCATTGAAGTCTCAT-3′ under the
following conditions: 94°C for 2 min, 35 cycles of 94 °C for 30 s, 58 °C for
30 s and then 72 °C for 30 s, followed by a final 5 min extension at 72 °C,
and held at 4 °C. PCR products were resolved on a 2% agarose gel, and the
exon 4 356 bp fragment was excised and purified using Wizard SV Gel and
PCR Cleanup Kit (Promega Cooperation). The purified DNA was sequenced
by the Sanger method using BigDye Terminator v.3.1 Cycle Sequencing Kit
(Applied Biosystems, Carlsbad, CA, USA) and a 3130xl Genetic Analyzer
(Applied Biosystems). Genotypes were identified by sequencing in both
forward and reverse directions. German samples were sequenced by next-
generation deep sequencing of the exons 4–11 of the TP53 gene using the
454 GS FLX amplicon chemistry (Roche Applied Science, Indianapolis, IN,
USA) as described previously.28 For London samples, 14 amplicons across
the entire TP53 coding region, including untranslated exon 1, were
sequenced using the Roche GS FLX sequencing platform (Roche,
Indianapolis, IN, USA) as described previously.29
Variable description
Clinical data on all patients was collected through March 2011, and
disease-specific features analyzed were limited to the date of diagnosis.
Genotype frequency did not differ across races among del(5q) MDS cases
(P= 0.54) or controls (P=1.0); however, there was a significant difference in
R72P genotype between Caucasian and non-Caucasian among non-del(5q)
MDS informative cases, or in those of which these data were available
(P= 0.05). As the proportion of non-Caucasian patients within each
subgroup was o10% (3.6% for del(5q), 10% for non-del(5q) and 3.6%
for controls), and we found no significant difference in R72P genotype by
race (P=0.21) in the total population, all analyses included all patients and
controls regardless of race. Cytogenetic risk was defined according to the
following criteria: low/good: normal, − Y and isolated 5q or 20q deletion as
single anomaly; intermediate (Int): 5q deletion plus one, or one
abnormality; and high/poor: any chromosome 7 abnormality or 2+
abnormalities. R72P genotype among World Health Organization (WHO)
subtypes was assessed by comparing genotype distribution across the
following categories: isolated del(5q), refractory anemia with excess blasts-
1 (RAEB-1), RAEB-2, RAEB-transformed (RAEB-T) and ‘other’, which included
refractory anemia (RA), RA with ring sideroblasts (RARS), refractory
cytopenia with multilineage dysplasia (RCMD) and RCMD with ring
sideroblasts; MDS/myeloproliferative neoplasm (MPN), AML and the non-
proliferative MDS/MPN chronic myelomonocytic leukemia (CMML).
Statistical analysis
Participants’ demographic features, R72P genotype and allele frequency
among controls and MDS (non-del(5q) and del(5q)) cases were compared
using the analysis of variance test for continuous variables and the χ2 test
using the exact method with Monte Carlo estimation for categorical
variables. The association between R72P genotype and disease features
was evaluated using the Fisher’s exact test. OS was defined as the interval
from the date of diagnosis until the date of death from any cause or until
the last date of follow-up. PFS was defined as the time from diagnosis to
development of AML or to date of death due to any cause, whichever
came first. The OS, PFS and lenalidomide transfusion independence
response duration were estimated using the time-to-event approach. For
the lenalidomide transfusion independence response duration, the data
were truncated at 4 years because only five patients had a response
beyond 4 years. The Kaplan–Meier curves by genotype were generated
and compared using the log-rank test. The genotype frequencies between
del(5q) MDS patients with deletions resolved by metaphase cytogenetics
were analyzed using the χ2 test using the exact method with Monte Carlo
estimation. All P-values ⩽ 0.05 were considered statistically significant. All
analyses were conducted using SAS (Version 9.2; SAS Institute Inc., Cary,
NC, USA).
RESULTS
Subject characteristics
A total of 705 MDS cases were analyzed (372 non-del(5q) and 333
del(5q)), as well as 157 healthy controls. The mean age in controls
was 53.3 years and ranged from 18 to 89 years (Table 1). Among
informative non-del(5q) MDS, the mean age was 68.5 years with a
range of 16–94 years, and for del(5q) patients mean age was 68.7
years and ranged from 23 to 93 years. The percentage of females
in each population was 52.8%, 32.2% and 66.5% in controls, non-
del(5q) and del(5q) MDS, respectively, as isolated 5q− is more
frequent in females; however, there were no genotype differences
by sex. WHO MDS subtype was available for 348 non-del(5q) cases,
which included 50 (14.4%) refractory anemia with excess blasts-1
(RAEB-1), 32 (9.2%) RAEB-2, 4 (1.1%) AML, 10 (2.9%) non-
proliferative MDS/MPN category of CMML, 4 (1.1%) MDS/MPN-
unclassified and 248 (71.3) ‘others’, which included the non-
blastic, morphologic subtypes of refractory anemia (RA), RARS,
RCMD and RCMD with ring sideroblasts. Within the del(5q) cohort,
WHO subtype was available for 309 cases, which included 179
(57.9%) patients with isolated del(5q) MDS, 28 (9.1%) with RAEB-1,
17 (5.5%) with RAEB-2, 5 (1.6%) with RAEB-T, 15 (4.9%) with AML, 2
(0.6%) with CMML and 63 (20.4%) with ‘other’ diagnoses (Table 1).
Of the 321 non-del(5q) cases with International Prognostic Scoring
System (IPSS) data, 254 (79.1%) were grouped as lower risk, which
included both low-risk and intermediate-1 IPSS values, whereas 67
(20.9%) were grouped as higher risk, which included intermediate-
2 and high-risk patients. Of the 164 del(5q) cases informative for
IPSS, 72% were lower-risk and 28% were higher-risk patients by
IPSS. Distribution of low, intermediate and high cytogenetic risk
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among 357 non-del(5q) patients was 265 (74.2%), 52 (14.6%) and
40 (11.2%), respectively, and 213 (68.9%), 21 (6.8%) and 75
(24.3%), respectively, among 309 del(5q) cases.
R72P genotype and disease status
To assess potential differences in allele distribution and frequency,
we first compared SNP genotype among controls and cases of
non-del(5q) and del(5q) MDS and found no significant differences
in R72P genotype (P= 0.13), including no significant difference
between the del(5q) vs non-del(5q) cases (P= 0.17). The frequency
of CC, CG and GG among controls, non-del(5q) and del(5q)
samples were 7.6%, 37.6% and 54.8%; 9.7%, 44.6% and 45.7%; and
12.6%, 38.1% and 49.2%, respectively (Table 1). There was no
significant difference in allele frequency in del(5q) MDS vs non-del
(5q) MDS cases (P= 0.91); however, differences between non-del
(5q) allele frequency and controls approached significance
(P= 0.08), as well as del(5q) cases, compared with controls
(P= 0.10). C-allele frequency for controls, non-del(5q) MDS and
del(5q) MDS was 26.4%, 32.0% and 31.7%, respectively (Table 1).
These findings suggest that there may be greater C-allele
frequency among MDS cases compared with controls.
R72P genotype and clinical characteristics
We next investigated whether R72P genotype was associated with
differences in disease features in del(5q) or non-del(5q) MDS cases
(Table 2). There was no correlation between IPSS category and
R72P in non-del(5q) patients (P= 0.42) with corresponding
frequencies for CC, CG and GG of 9.4%, 46.1% and 44.5% for
lower-risk and 11.9%, 37.3% and 50.7% for higher-risk MDS,
respectively. In del(5q) MDS, the frequencies of CC, CG and GG
were 16.9%, 48.3% and 34.7% for lower-risk and 13%, 34.8% and
52.2% for higher-risk IPSS patients, respectively, with no correla-
tion between IPSS and genotype (P= 0.12) (Table 2). There was a
difference in R72P genotype distribution by WHO classification in
non-del(5q) MDS cases with an increasing frequency of the CC
genotype corresponding to increased bone marrow blast percen-
tage (P= 0.04); however, this represents only a small proportion of
patients in our study. There was no relationship between WHO
classification and R72P genotype in del(5q) MDS (P= 0.37). We
next examined the relationship between R72P genotype and age
of disease onset among MDS cases. We found no significant
difference in age at diagnosis according to R72P genotype among
patients with either non-del(5q) (mean± s.d. was 65.3 ± 11.2,
65.4 ± 12.9 and 62.5 ± 13.5, for CC, CG and GG, respectively) or
del(5q) MDS (66.6 ± 10.5, 64.1 ± 13.8 and 65.9 ± 11.6, for CC, CG
Table 2. R72P genotype frequency by clinical characteristics
Non-del (5q) Del (5q)
CC CG GG CC CG GG
IPSS grouping (%), n 10 (32) 44.2 (142) 45.85 (147) 15.9 (28) 44.5 (73) 39.6 (65)
Low 9.4 (24) 46.1 (117) 44.5 (113) 16.9 (20) 48.3 (57) 34.7 (41)
High 11.9 (8) 37.3 (25) 50.7 (34) 13 (8) 34.8 (16) 52.2 (24)
P-value 0.421 0.119
Cytogenetics risk group (%), n 9.5 (34) 45.4 (162) 45.1 (161) 12.3 (38) 37.2 (115) 50.5 (156)
Iso-del(5q) or NA 9.8 (26) 45.7 (121) 44.5 (118) 10.8 (23) 37.6 (80) 51.6 (110)
Del(5q)+/1 Ab 9.6 (5) 44.2 (23) 46.2 (24) 9.5 (2) 52.4 (11) 38.1 (8)
Complex 7.5 (3) 45 (18) 47.5 (19) 17.3 (13) 32 (24) 50.7 (38)
P-value 0.992 0.325
WHO classification 9.8 (34) 45.5 (158) 44.7 (155) 12.6 (39) 38.2 (118) 49.2 (152)
Isolated del(5q) 0 (0) 0 (0) 0 (0) 8.9 (16) 36.3 (65) 54.7 (98)
RAEB-1 4 (2) 54 (27) 42 (21) 17.9 (5) 39.3 (11) 42.9 (12)
RAEB-2 18.8 (6) 28.1 (9) 53.1 (17) 11.8 (2) 52.9 (9) 35.3 (6)
RAEB-T 0 (0) 0 (0) 0 (0) 20 (1) 40 (2) 40 (2)
RA, RARS, RCMD, RCMD-RS 9.3 (23) 46.6 (115) 44.1 (109) 17.5 (11) 39.7 (25) 42.9 (27)
CMMLa 30 (3) 50 (5) 20 (2) 0 (0) 0 (0) 100 (2)
AML 0 (0) 0 (0) 100 (4) 26.7 (4) 40 (6) 33.3 (5)
P-value 0.041 0.372
%, n Abbreviations: AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; IPSS, International Prognostic Scoring System; MDS,
myelodysplastic syndrome; MPN, myeloproliferative neoplasm; RA, refractory anemia; RAEB-1, refractory anemia with excess blasts-1; RARS, RA with ring
sideroblasts; WHO, World Health Organization. aNon-proliferative MDS/MPN.
Table 1. Case–control comparison of R72P genotype
Control Non-del(5q) Del(5q)
Total, n 157 372 333
Age at sampling, (mean, range) 53.3,
18–89
68.5,
16–94
68.7,
23–93
Percent female, n 52.8 (85) 32.2 (120) 66.5 (216)
Percent Caucasian, n 95.9 (94) 90 (325) 96.4 (187)
WHO classfication, n 348 309
Isolated 5q 0 (0) 57.9 (179)
RAEB-1 14.4 (50) 9.1 (28)
RAEB-2 9.2 (32) 5.5 (17)
RAEB-T 0 (0) 1.6 (5)
MDS/MPN 1.1 (4) 0 (0)
CMML 2.9 (10) 0.6 (2)
AML 1.1 (4) 4.9 (15)
Other 71.3 (248) 20.4 (63)
CC genotype (%), n 7.6 (12) 9.7 (36) 12.6 (42)
CG genotype (%), n 37.6 (59) 44.6 (166) 38.1 (127)
GG genotype (%), n 54.8 (86) 45.7 (170) 49.2 (164)
C-allele frequency (%) 26.43 31.99 31.68
G-allele frequency (%) 73.57 68.32 68.01
Abbreviations: AML, acute myeloid leukemia; CMML, chronic myelomono-
cytic leukemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative
neoplasm; RAEB-1, refractory anemia with excess blasts-1; WHO, World
Health Organization.
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and GG, respectively) (P= 0.08 and P= 0.69, respectively). Age at
diagnosis did decrease with G-allele homozygozity in non-del(5q)
MDS and approached significance when comparing the age at
diagnosis in patients harboring the GG genotype between non-del
(5q) and del(5q) MDS patients (P= 0.07).
R72P genotype and disease natural history
To investigate possible differences in outcome by R72P genotype,
we assessed OS and PFS. There was no significant difference in OS
by genotype among all MDS cases (log-rank test, P= 0.64), where
5-year OS was 0.46, 0.56 and 0.49 for CC, CG and GG, respectively
(Figure 1). Among non-del(5q) cases, median survival by genotype
was 4.5 years for CC, 10.2 years for CG and 5.3 years for GG
(P= 0.39). However, 1-year survival increased in a G-allele dosage
manner with survival estimates of 0.83, 0.96 and 0.98 for CC, CG
and GG. Among del(5q) MDS patients, the median OS was 4.9
years for CC, 5.1 years for CG and 4.0 years for GG (P= 0.52) with
41-year survival associated with the C-allele (0.82, 0.77 and 0.73
for CC, CG and GG, respectively). Although there was no significant
differences in PFS in del(5q) MDS by R72P genotype (P= 0.53) or
non-del(5q) MDS (P= 0.61), the CC genotype showed a trend of
overall improved PFS than G-allele-containing genotypes in del
(5q) MDS, whereas G-allele-containing genotypes were associated
with improved PFS and OS in non-del(5q) MDS (Figure 2). When
comparing the interaction of the R72P genotype with other
prognostic variables (i.e., age at diagnosis, cytogenetics, blast
percentage and gender) by multivariate analysis, only IPSS
retained prognostic significance for OS and PFS.
R72P genotype and lenalidomide response duration
We previously reported that lenalidomide modifies p53 stability,
which facilitates G1 escape and transition to G2 arrest in del(5q)
progenitors.30,31 To determine if TP53 R72P SNP genotype
influences lenalidomide response or duration, we explored the
relationship between R72P genotype and duration of erythroid
response to lenalidomide treatment in del(5q) patients. Erythroid
response was defined using the previously described criteria.1,2,32
Although we found no significant difference in response rates by
genotype (P= 0.75) (73.5% overall response rate, 71.4% for CC,
77.5% for CG and 69.0% for GG), comparison of response duration
by genotype showed a trend for increased duration of transfusion
independence with C-allele dosage; however, this did not reach
statistical significance (P= 0.51) (Figure 3). Median response
durations according to genotype were 2.2, 1.3 and 0.89 years for
CC, CG and GG genotypes, respectively. Interestingly, the 2-year
estimate for lenalidomide response duration was more than
doubled for CC (0.50) compared with both CG (0.21) and GG (0.13)
(P= 0.09).
Chromosome 5q deletion size, TP53 mutation and R72P genotype
Size of the deletion on chromosome 5q varies from microdele-
tions to large terminal deletions. The larger, more terminal lesions,
particularly those including or extending telomeric to 5q34, have
been linked to higher-risk MDS and AML, and unfavorable
prognosis. To ascertain the relationship between R72P genotype
and extended terminal chromosome deletions, we investigated
genotype distribution by deletion inclusion of chromosome 5q34
deletion (Figure 4a). Using a cohort of 190 del(5q) patient
Figure 1. Kaplan–Meier estimates of OS according to R72P genotype. Non-del(5q) MDS (left) and del(5q) MDS (right).
Figure 2. Kaplan–Meier estimates of PFS according to R72P genotype. Non-del(5q) MDS (left) and del(5q) MDS (right).
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specimens, chromosome 5 deletion location was assessed by
diagnostic metaphase cytogenetics. We found that the GG
genotype was significantly associated with those patients harbor-
ing a deletion involving 5q34 (P= 0.05) compared with those
patients with a C-allele-containing genotype. The frequency of a
5q34 deletion in either CC or CG samples was 50%; however, this
increased to 71% for those with a GG genotype. Jerez et al.33
recently reported an association between larger chromosome 5
deletions and TP53 mutations;33 therefore, we next examined the
relationship between R72P genotype and TP53 DNA-binding
domain mutation. Among the 211 del(5q) cases with TP53
mutation analysis, 30.3% contained a DNA-binding domain
mutation; however, there was no association with R72P genotype
(CC, 45.5, CG, 23.9 and GG, 31.4%). Among those patients
harboring the 5q34 deletion, we found no association with TP53
mutation (P= 0.33) (Figure 4b). Lastly, we found no association
between GG genotype and TP53 mutation in the del(5q) cases
(P= 0.38) (Figure 4c). There was no association with TP53 mutation
and any R72P genotype in either del(5q) MDS (P= 0.15) or non-del
(5q) MDS (P= 1.0).
DISCUSSION
Gene deletion studies indicate that the p53 polyproline domain
is essential to mount an effective apoptotic response to stress
and inhibit tumorigenesis.34-37 P53-P72 binds more weakly than
p53-R72 to the positive regulatory protein PIN1, a prolyl
isomerase,38 yet interacts more readily with the inhibitory protein
iASPP (inhibitor of ASPP).39 We found no differences in age of MDS
onset by R72P genotype; however, germline gene mutations
implicated in the development of familial MDS, such as the Runt-
related transcription factor-1 (RUNX1), similarly show no consistent
association with earlier onset of disease, suggesting that
secondary events necessary for MDS development are age-
dependent.40–42
A significant finding in this study was the association of the
G-allele and GG homozygous genotype with more terminal 5q34
deletions (P= 0.05). Previous studies reported that patients with
larger terminal deletions have a less favorable prognosis and
higher frequency of TP53 mutation.33 Although we did not discern
a relationship to gene mutation status, the overall frequency of
TP53 gene mutation was relatively low. Nonetheless, the precise
mechanisms driving the differences in deletion loci by R72P
genotype remain unclear. The P72 (CC) variant is reported to be
more efficient in inducing cell-cycle arrest and DNA repair than
the R72 variant, which may account for the longer OS and PFS in
del(5q) patients harboring the C-allele or CC genotype.23,43 By
contrast, in patients with non-del(5q) MDS, we found that OS and
PFS were reduced in those individuals harboring the CC genotype.
We hypothesize that in non-del(5q) MDS in which the hemato-
logic phenotype is not p53-dependent, the attenuated apoptotic
Figure 4. Chromosome 5q deletion by R72P genotype. (a) Association of 5q34 deletion with R72P genotype, (b) association of TP53 mutation
with 5q34 deletion and (c) association of TP53 mutation and R72P genotype in del(5q) MDS.
Figure 3. Kaplan–Meier estimate of lenalidomide (LEN) response
duration in del(5q) MDS patients.
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activity of the C-allele/P72 variant may facilitate emergence and
survival of clones with greater AML potential.
Although we were unable to discern significant differences in
the duration of transfusion independence to lenalidomide
according to genotype in del(5q) MDS patients, there was a trend
favoring longer response duration in patients with a C allele that
appears allele dosage dependent. As lenalidomide suppresses del
(5q) MDS clones by inhibiting the dual specificity phosphatases
CDC25C and PP2Acα encoded within or adjacent to the 5q31
commonly deleted region to arrest progenitors in G2/M, we
questioned whether the diminished apoptotic capacity of the
homozygous CC phenotype might foster transition from G0/G1
and sustained G2/M arrest to account for the more prolonged
response duration. Furthermore, given that approximately half of
lenalidomide-treated patients become resistant to treatment
within 3 years, the lack of significant differences in 5-year
response duration is not surprising.1
These data underscore the distribution of R72P in MDS and
highlight differences between del(5q) and non-del(5q) subtypes
by gene polymorphism and the relationship to lenalidomide
response. The potential interaction of R72P variants with germline
variants in other key regulators or effectors of the p53 pathway
that may modify MDS risk and lenalidomide response merit
further investigation in a larger cohort of patients.
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